DLBCL Prognosis & Management in Front-line Settings #oncology #lungcancer #cancer #2023

Discussing two important lymphoma studies, POLARIX which led to the approval of Polatuzumab in DLBCL patients and SWOG S1826 comparing Nivolumab vs. BV with AVD in Hodgkin's Lymphoma patients with Dr. Jonathan Friedberg. In discussion with the lead author, Dr. Jonathan Friedberg - Director of Wilmot Cancer Institute, Professor of Medicine at University of Rochester Medical Center, and Editor-in-Chief at Journal of Clinical Oncology (JCO).

#immunotherapy #oncology #fda #polatuzumab #nivolumab #2023 #cancer #oncbrothers

Twitter:

/ oncbrothers